52 Articles in August 2026
What would it take to get peptides on the shelf?
What Would It Take to Get Peptides on the Shelf? NPR Report Spotlights Regulatory Crossroads for Booming Industry A recent NPR report poses a deceptively simple question that has become one of the most consequential regulatory puzzles in American health and wellness: what would it actually take to ...
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug Retatrutide, an experimental weight-loss and metabolic drug developed by Eli Lilly, is drawing intense attention from investors, physicians, and regulators alike, with some analysts projecting the broader obesity-drug market could event...
August 10, 2026: Compounded peptide injections recalled due to high endotoxin levels
Compounded Peptide Injections Recalled Over Endotoxin Contamination Concerns A recall of compounded peptide injection products has been issued after testing revealed elevated endotoxin levels, according to the Partnership for Safe Medicines, a nonprofit organization that tracks drug safety and coun...
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last
Hims & Hers Shares Dip as FDA Signals Scrutiny of GLP-1 Marketing by Telehealth Providers Shares of Hims & Hers Health slipped in overnight trading after reports emerged that the U.S.
Banned from sport over peptides: Kiwi world champion says he didn’t know he was doing anything wrong
New Zealand Athlete's Doping Ban Highlights Growing Peptide Regulatory Confusion A New Zealand world champion has been banned from competition after testing positive for banned peptides, telling reporters he was unaware he had done anything wrong, according to a report published by Stuff.
The FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs
FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs, Legal Experts Say The Food and Drug Law Institute (FDLI) has weighed in on one of the most contentious regulatory disputes in pharmaceutical law today, arguing that the Food and Drug Administration's efforts to curb mass production...
5 Things to Know About the FDA's Peptide Reversal
FDA's Shifting Stance on Peptides Sends Ripples Through Compounding Industry The U.S.
FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead
FDA Advisory Committee Voted Yes on Six Peptides.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding certain unapproved peptide drugs to the agency's compounding lists, according to reporting from the Partnership for ...
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
Eli Lilly Escalates Legal Fight Against Peptide Vendors Selling Unapproved Retatrutide Eli Lilly and Company has filed lawsuits against a number of pharmacies and peptide vendors accused of manufacturing, marketing, and selling retatrutide, the pharmaceutical giant's experimental triple-hormone rec...
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
The 2026 GLP-1 Compounding Crackdown: What Pharmacists Need to Know Compounding pharmacies that have built substantial business lines around semaglutide and tirzepatide are bracing for intensified federal scrutiny as the calendar turns toward 2026, according to a report from Drug Topics titled "The...
FDA on Peptides: A New Landscape for Compounders
FDA on Peptides: A New Landscape for Compounders Washington, D.C.
One Year Later: Lessons in Compounding Compliance
Overview of the Regulatory Action The RealClearHealth commentary "One Year Later: Lessons in Compounding Compliance" arrives at a natural inflection point for the pharmacy compounding industry, marking roughly twelve months since the U.S.
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
This article is based on limited source information from a CBS News report referenced via Google News. Some contextual details reflect established public reporting on Eli Lilly's broader anti-counterfeiting and anti-diversion efforts regarding its weight-loss and diabetes drug portfolio.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide Eli Lilly and Company has filed lawsuits against six companies accused of illegally selling retatrutide, the pharmaceutical giant's experimental triple-agonist obesity drug that has not yet received approva...
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide
Eli Lilly Targets Gray-Market Sellers of Experimental Weight-Loss Drug Eli Lilly and Company has filed six separate lawsuits aimed at shutting down what the pharmaceutical giant describes as a burgeoning "black market" for retatrutide, an experimental triple-hormone receptor agonist still undergoin...
Lilly takes 6 companies to court for selling retatrutide knockoffs
Eli Lilly Sues Six Companies Over Alleged Retatrutide Knockoffs Eli Lilly and Company has filed lawsuits against six companies accused of manufacturing, marketing, or distributing unauthorized versions of retatrutide, the pharmaceutical giant's investigational triple-hormone receptor agonist that h...
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Eli Lilly Moves to Shut Down Alleged Black Market Sales of Experimental GLP-1 Drug Eli Lilly and Company has taken action against alleged black market sales of one of its experimental GLP-1 receptor agonist drugs, according to a report from The Hill.
An FDA Advisory Panel Voted to Ease Restrictions on 6 Controversial Peptides—Here’s What That Means
FDA Advisory Panel Reportedly Backs Loosening Restrictions on Six Contested Peptides A Food and Drug Administration advisory panel has reportedly voted in favor of easing restrictions on six peptides that have been at the center of an ongoing regulatory dispute, according to a report from Allure.
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides State legislatures and pharmacy boards across the country are moving to impose their own restrictions on compounded GLP-1 medications and peptide products, adding a new layer of regulatory complexity for an industry t...
Navigating Compounding Peptides and GLP-1s Through Regulations
Overview of the Regulatory Action The compounding of glucagon-like peptide-1 (GLP-1) receptor agonists and other peptide-based therapeutics has become one of the most closely watched flashpoints in pharmaceutical regulation over the past two years.
TGA Fines for Importing Peptides to Australia: 2024-2025 Complete Guide
Overview of the Regulatory Action Australia's Therapeutic Goods Administration (TGA) has intensified scrutiny of research peptides such as BPC-157, TB-500, CJC-1295, and Ipamorelin, treating their importation for human use as a violation of the Therapeutic Goods Act 1989 (Cth).
Australian TGA Personal Importation Scheme: Can You Legally Import Peptides?
Australian TGA Personal Importation Scheme: Can You Legally Import Peptides? Australians seeking to import research peptides and growth hormone secretagogues for personal use face a significant legal obstacle: the Therapeutic Goods Administration's (TGA) Personal Importation Scheme, widely believed...
Growth Hormone Secretagogues Australia: TGA Classification and Legal Status
Growth Hormone Secretagogues in Australia: Prescription-Only Status Carries Serious Legal Risk for Unauthorized Importation Australians seeking growth hormone secretagogues such as Ipamorelin, CJC-1295, GHRP-2, GHRP-6, Sermorelin, and MK-677 (Ibutamoren) face a strict regulatory environment that cl...
Australian Border Force Peptide Seizures: What Happens When Your Package is Stopped
Australian Border Force Peptide Seizures: What Happens When Your Package is Stopped Australians ordering peptides online are increasingly encountering a hard truth at the border: packages containing these substances are being flagged, held, and in many cases seized by Australian Border Force (ABF) ...
BPC-157 Legal Status in Australia: TGA Regulations Explained
Overview of the Regulatory Action BPC-157, a synthetic peptide derived from a fragment of a protein found in human gastric juice, has become one of the most searched-for compounds in the peptide and performance-enhancement communities worldwide.
Are Peptides Illegal in California? State Laws Explained
Are Peptides Illegal in California? What the Current Rules Actually Say Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding ph...
California Peptide Therapy Laws: What Doctors and Patients Need to Know
California Peptide Therapy Laws: What Doctors and Patients Need to Know Disclaimer: This article summarizes general regulatory frameworks governing peptide therapy in California. It is intended as background information for healthcare providers and patients, not as legal or medical advice.
Texas Peptide Laws 2024: Regulations for BPC-157, TB-500, and More
Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's ...
Florida Peptide Regulations: State Law Guide for 2024
Florida Peptide Regulations: What Compounders, Clinics, and Consumers Need to Know Peptide therapies—ranging from BPC-157 to semaglutide analogs sold outside FDA-approved branded products—have become a flashpoint for state and federal regulators. Florida is no exception.
FDA panel supports broadening access to peptides popular on the gray market
FDA Advisory Panel Signals Openness to Expanding Legal Access to Popular Peptide Compounds A Food and Drug Administration advisory panel has expressed support for broadening legitimate access to certain peptide compounds that have gained significant popularity through gray-market channels, accordin...
How the FDA Regulates Peptides
How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusin...
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA Advisory Panel Set to Weigh In on Contested Peptide Compounds Amid Growing Industry Tension A forthcoming Food and Drug Administration advisory committee meeting is expected to become a flashpoint in the ongoing debate over the regulatory status of popular research and wellness peptides, accord...
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
California Pharmacy Regulators Weigh Response to Federal Peptide Prescribing Debate A recent advisory panel vote at the U.S.
FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype
FDA's Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype A recent Forbes report has drawn renewed attention to the Food and Drug Administration's ongoing scrutiny of the peptide industry, highlighting what the publication frames as a growing public health ch...
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
Novo Nordisk Prevails in Netherlands Legal Battle Over Compounded GLP-1 Products Novo Nordisk has secured a legal victory in the Netherlands in a lawsuit concerning compounded versions of its GLP-1 receptor agonist medications, according to a report from pharmaphorum.
Troubling Findings in Study of GLP-1 Compounders
Troubling Findings in Study of GLP-1 Compounders A new study examining compounded versions of popular GLP-1 receptor agonist drugs has surfaced concerning findings, according to a report from MedPage Today, adding fresh scrutiny to an industry that expanded rapidly during a nationwide shortage of b...
FDA panel backs 6 peptides despite its own scientists’ objections
FDA Panel Backs Six Peptides Despite Internal Scientific Objections A Food and Drug Administration advisory panel has voted to support the use of six peptide compounds for compounding, moving forward despite documented objections from the agency's own scientific staff, according to a report from Ma...
August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”
Peptide Vendor Sentenced to Six Years in Federal Case Highlighting Dangers of Unregulated Peptide Market A peptide vendor has been sentenced to six years in federal prison following a prosecution that a federal judge reportedly described as leaving behind an "incredible trail of harm," according to...
FDA puts former Rancho Santa Fe pharmacist on notice for selling unapproved weight-loss injections online
FDA Targets Former Rancho Santa Fe Pharmacist Over Online Weight-Loss Injection Sales The U.S.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding a group of unapproved peptide drugs to the agency's compounding list, according to reporting from the Partnership fo...
The five risks of taking unapproved peptides
Partnership for Safe Medicines Report Highlights Growing Dangers in Unregulated Peptide Market The Partnership for Safe Medicines, a nonprofit coalition focused on drug safety and public health, has published a report identifying five key risks associated with the use of unapproved peptides — a r...
FDA advisers back first four of seven unapproved peptides under review for looser rules
FDA Advisory Panel Recommends Looser Rules for Four Unapproved Peptides, With Three More Under Review A Food and Drug Administration advisory committee has voted to support looser regulatory treatment for four of seven unapproved peptide compounds currently under agency review, according to a repor...
Peptides May Soon Be Legal. These Companies Are Ready To Cash In
Peptides May Soon Be Legal: Industry Players Position Themselves Ahead of Potential Regulatory Shift A new report from Forbes signals that the regulatory landscape for peptide-based products may be on the verge of significant change, with companies across the supplement, wellness, and pharmaceutica...
FDA panel to review popular peptides amid persistent consumer appetite
FDA Panel to Review Popular Peptides Amid Persistent Consumer Appetite The U.S.
FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
FDA Advisory Panel Backs Expanded Peptide Compounding Over Objections From Agency's Own Scientists A Food and Drug Administration advisory panel has voted to recommend adding certain peptides to the list of substances that compounding pharmacies are permitted to use, a decision reached despite push...
FDA panel votes to loosen restrictions for controversial peptides
FDA Advisory Panel Votes to Ease Restrictions on Controversial Peptide Compounds A Food and Drug Administration advisory panel has voted to loosen restrictions on a category of peptide compounds that have been at the center of an ongoing regulatory debate, according to a report from the BBC.
An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
FDA Advisory Panel Breaks With Agency Staff, Backs Continued Access to Peptide Compounds A Food and Drug Administration advisory committee has voted in favor of preserving broader access to certain peptide-based compounds, setting up a notable clash with the agency's own staff recommendations, acco...
FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules
FDA Panel to Revisit Biden-Era Peptide Restrictions Amid Push for Regulatory Flexibility A Food and Drug Administration advisory panel is preparing to reexamine restrictions placed on a category of therapeutic peptides during the Biden administration, according to a report from Bloomberg Law News.
How wellness clinics bend the rules to supply unapproved peptides and anti-ageing injections
Wellness Clinics Skirt Regulatory Barriers to Sell Unapproved Peptides and Anti-Ageing Injections A growing network of wellness clinics across the country is exploiting regulatory loopholes to market and administer unapproved peptide therapies and anti-ageing injections, according to reporting from...
Compounded GLP-1s: Why doctors worry and the FDA is cracking down
Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down The explosive popularity of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and diabetes management has spawned a booming secondary market: compounded versions of these drugs, sold at a fraction of brand-name...
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides As federal oversight of compounded GLP-1 medications and research peptides continues to evolve at the U.S.